Contrast-induced nephropathy, now more accurately referred to as contrast-associated acute kidney injury, is a potential decline in kidney function following an examination or procedure involving iodinated contrast media. This guide is intended for patients, general practitioners and vascular teams: it explains symptoms, consequences and practical measures to reduce the risk, especially in patients with kidney impairment.
The key is to distinguish the actual risk from oversimplifications: iodinated contrast does not automatically damage the kidneys, but in some vulnerable patients it may contribute to a deterioration in kidney function. Prevention begins before the procedure, with an individual clinical assessment and the selection of the most suitable imaging technique.
The historical term CIN stands for Contrast-Induced Nephropathy, meaning kidney damage caused by contrast media. Today, contrast-associated AKI is often used instead: AKI stands for Acute Kidney Injury. The term "associated" is more cautious because dehydration, infection, heart failure, hypotension, medications or the complexity of the intervention may also play a role after a procedure.
According to the criteria established by KDIGO, the international organisation that defines standards for kidney disease, AKI is present when blood creatinine increases by at least 0.3 mg/dL within 48 hours or reaches at least 1.5 times the baseline value within seven days. A creatinine blood test is used to estimate the kidneys' filtration capacity.
Contrast-associated AKI often causes no obvious symptoms in its early stages. For this reason, checking creatinine after the procedure in patients at risk is more reliable than relying on symptoms alone.
When present, signs may include reduced urine output, swelling in the legs or ankles, unusual tiredness, nausea, shortness of breath or confusion. These symptoms are not specific to kidney injury and require prompt medical assessment, particularly if they occur within 48–72 hours after angiography.
The risk is particularly increased in people with chronic kidney disease, a persistent reduction in kidney function. The most commonly used measure is eGFR, or estimated Glomerular Filtration Rate: an estimate of the kidneys' filtration capacity reported in blood test results.
A low eGFR, diabetes, dehydration, heart failure, advanced age, anaemia, low blood pressure during the procedure and the use of large amounts of iodinated contrast can have a cumulative effect. An urgent or complex procedure can also increase the overall risk. The presence of one or more factors does not mean that angiography cannot be performed: it means that more careful planning is needed.
Many episodes of AKI are temporary, and kidney function recovers over the following days or weeks. However, acute kidney injury can prolong hospitalisation, complicate medication and fluid management and, in more severe cases, require specialist nephrology care or dialysis.
In patients who are already vulnerable, AKI is associated with more complications during hospitalisation and a greater risk of persistent loss of kidney function. The aim is therefore not to avoid necessary examinations or interventions, but to obtain the required clinical information with the lowest reasonably achievable burden on the kidneys.
1. Measure creatinine and eGFR before the procedure in patients at risk.
Baseline results allow the team to classify the risk and accurately compare subsequent test results. In an emergency, the decision balances the renal risk against the risk of delaying necessary treatment.
2. Correct dehydration and develop an individualised hydration plan.
Intravenous hydration with normal saline is one of the most established preventive strategies in selected patients. It must be tailored by the physician, particularly in people with heart failure, to avoid fluid overload.
3. Reduce the dose of iodinated contrast or use an alternative where appropriate.
The team may choose low-volume contrast protocols, complementary imaging techniques or, for vascular procedures below the diaphragm, carbon dioxide angiography. The choice depends on the anatomy, the procedure and clinical contraindications.
4. Review medications and clinical conditions that increase the risk.
The physician assesses potentially nephrotoxic medications, haemodynamic status and coexisting conditions. Patients must not stop taking any medication on their own: the management of diuretics, anti-inflammatory medications or diabetes treatments requires individualised advice.
5. Check kidney function after the procedure when indicated.
In patients at risk, checking creatinine within the following 48–72 hours allows any deterioration to be identified early so that action can be taken. Acetylcysteine and bicarbonate have not shown a consistent advantage over normal saline in large prevention trials.
In angiography, contrast media make blood vessels visible on X-ray images. Carbon dioxide, referred to as CO₂, can be used as a gaseous contrast agent in selected vascular procedures below the diaphragm, for example in peripheral arterial disease. It is not a universal solution: it requires expertise, a protocol and an assessment of contraindications.
For patients with chronic kidney disease, diabetes or a previous reaction to iodinated contrast, a contrast-sparing strategy can significantly reduce the volume of iodinated contrast used. Automated, digital systems, such as the Angiodroid CO₂ injector, help standardise injection volume, pressure and timing, making the workflow more traceable than manual injection.
In Europe, vascular and interventional radiology centres use CO₂ mainly for peripheral revascularisation and procedures in patients with impaired kidney function. Available evidence, including systematic reviews of studies on peripheral interventions, indicates that CO₂ substantially reduces the volume of iodinated contrast used. A reduction in AKI episodes is clinically plausible and has been observed in many case series, but the exact estimate varies according to patient characteristics and the centre's protocol.
A useful example is not a promise of a particular outcome, but an organisational model: centres adopting automated CO₂ systems combine technology, patient selection, training and creatinine monitoring. This approach allows comparisons of iodinated contrast volume, AKI, length of hospital stay, readmissions and the need for nephrology consultations before and after implementation.
In Italy, a DRG, or diagnosis-related group used to classify and reimburse hospital admissions, does not equate to the actual cost of treating an individual patient. AKI can generate additional costs that are not always fully covered by the DRG payment, such as extra days in hospital, tests, specialist consultations or intensive treatment. It is therefore inappropriate to claim a standard DRG-related saving for every hospital: the economic benefit must be calculated using local data, alongside renal outcomes.
For hospital medical directors, a well-designed CO₂ project can therefore be assessed as a preventive care pathway: less iodinated contrast in appropriate patients, lower exposure to renal risk and traceable data for a business case based on outcomes, resource use and quality of care.
Patients can ask whether their eGFR results are up to date, whether iodinated contrast will be used and in what quantity, which hydration or monitoring measures are indicated and whether suitable alternatives are available for their case. It is important to report any previous kidney problems, diabetes, heart failure, allergies and all medications being taken.
The final decision rests with the treating team. Necessary angiography should not be postponed without clinical consultation: in many situations, the diagnostic or therapeutic benefit outweighs the risk, particularly when AKI prevention protocols are in place.
Angiodroid supports vascular surgery and interventional radiology teams through workflow assessment, clinical training and CO₂ implementation pathways for selected peripheral procedures. Request a technical and clinical consultation to define measurable indicators: iodinated contrast volume, AKI, length of hospital stay, readmissions and organisational impact.
Request an assessment of your CO₂ and Zero Contrast pathway
Does contrast-induced nephropathy always cause symptoms?
No. Contrast-associated acute kidney injury often causes no symptoms initially and is identified by checking creatinine. Reduced urine output, swelling, nausea or shortness of breath require prompt contact with a medical professional.
Can people with kidney impairment undergo angiography?
Yes. When clinically necessary, angiography can be performed even in patients with kidney impairment. The team assesses eGFR, associated conditions, hydration, the amount of iodinated contrast and possible contrast-sparing strategies to reduce the risk.
Can CO₂ always replace iodinated contrast media?
No. CO₂ is an alternative that can be used in selected vascular procedures below the diaphragm and is not suitable for every anatomical region or patient. It can reduce or, in appropriate cases, eliminate the need for iodinated contrast, but it requires suitable equipment and trained operators.
Does drinking plenty of water before contrast administration protect the kidneys?
Hydration may help, but vulnerable patients or those with heart failure should not manage it on their own. The physician determines whether oral or intravenous fluids are needed and prescribes the appropriate regimen.
Does reducing iodinated contrast use generate DRG-related cost savings for hospitals?
It may reduce costs associated with avoidable renal complications, but there is no DRG-related saving that applies equally to every hospital. A proper assessment compares local data on AKI, length of hospital stay, readmissions, resource use and reimbursement for hospital admissions.